BOT - Anything but charting, page-6982

Personally, I haven't given dividends much thought because I think we're years off from that position. When Sofrda starts making us money, all of those funds will need to be directed to progressing the pipeline of products, at least for the next couple of years I expect. Maybe management will throw shareholders a bone and provide a small portion of income as divvies, maybe not. On the one hand, Matt talks about taking BOT to being a major derma company, but he also talks about selling it if the right price came along. So hard to know if we would actually get to dividends before a lucrative offer came along and BOT got sold.